Crossmark

Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation

Crossref DOI link: https://doi.org/10.1007/s12640-018-9991-2

Published Online: 2019-01-03

Published Print: 2019-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Crunfli, Fernanda https://orcid.org/0000-0002-2968-8115
Vrechi, Talita A.

Costa, Andressa P.

Torrão, Andréa S.
Funding

Funding for this research was provided by:

Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/06372-0)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (1233360, 1279985)
License Information

Text and Data Mining valid from 2019-01-03
More Information

Article History

Received: 5 September 2018

Revised: 11 December 2018

Accepted: 14 December 2018

First Online: 3 January 2019

Compliance with Ethical Standards

: The experimental protocol was evaluated and approved by the “Ethics Committee for Animal use” of the Institute of Biomedical Sciences, University of São Paulo (Protocol no. 33/55/02) following the Brazilian Federal Law (no. 11794; 10/08/2008). All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

: The authors declare that they have no conflict of interest.